Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;5(3):553-9.
doi: 10.2147/tcrm.s6178. Epub 2009 Aug 3.

Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency

Danilo Fintini  1 , Claudia Brufani, Marco Cappa
Affiliations

Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency

Danilo Fintini et al. Ther Clin Risk Manag. 2009 Jun.

Abstract

Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug Administration only in 2005 and in Europe by the European Medicines Agency in 2007. To date, few studies are available on long-term treatment with mecasermin in IGFD patients and some of them have a very small number of subjects. In this review we discuss briefly clinical features of severe primary IGFD, laboratory findings, and indications for treatment. Results of long-term therapy with rhIGF1 (mecasermin) in patients affected by severe primary IGFD and possible side effects are explained.

Keywords: IGF-1; Laron syndrome; mecasermin; therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kronenberg H, Melmed S, Polonsky K, Larsen PR. Williams Textbook of Endocrinology. 11th edition . Burlington, MA: Elsevier; 2007.
    1. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab. 2004;89(3):1031–1044. - PubMed
    1. Norman P. Mecasermin Tercica . Curr Opin Investig Drugs. 2006;7(4):371–380. - PubMed
    1. Rosenbloom AL. Mecasermin (Recombinant Human Insulin-like Growth Factor I) Adv Ther. 2009;26(1):40–54. - PubMed
    1. Berg MA, Peoples R, Pérez-Jurado L, et al. Receptor mutations and haplotypes in growth hormone receptor deficiency: a global survey and identification of the Ecuadorean E180splice mutation in an oriental Jewish patient. Acta Paediatr Suppl. 1994;399:112–114. - PubMed